A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

Trial Profile

A MULTICENTER, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results (n=148) conducted integrated analysis of cardiovascular adverse events in newly diagnosed,transplant ineligible multiple myeloma patients treated with Carflizomib in IST-CAR-506, IST-CAR-561, IST-CAR-601 studies, presented at the 22nd Congress of the European Haematology Association.
    • 10 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results of integrated analysis of cardio-vascular events from three studies including this study presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top